These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 18541682)

  • 21. Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation.
    Weiss R
    Vasc Health Risk Manag; 2006; 2(3):303-8. PubMed ID: 17326335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of the new beta-blockers in treating cardiovascular disease.
    Weber MA
    Am J Hypertens; 2005 Dec; 18(12 Pt 2):169S-176S. PubMed ID: 16373195
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nebivolol in the treatment of chronic heart failure.
    Veverka A; Salinas JL
    Vasc Health Risk Manag; 2007; 3(5):647-54. PubMed ID: 18078016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and tolerability of nebivolol in stage I-II hypertension: a pooled analysis of data from three randomized, placebo-controlled monotherapy trials.
    Weiss RJ; Saunders E; Greathouse M
    Clin Ther; 2011 Sep; 33(9):1150-61. PubMed ID: 21864908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study.
    Giles TD; Weber MA; Basile J; Gradman AH; Bharucha DB; Chen W; Pattathil M;
    Lancet; 2014 May; 383(9932):1889-98. PubMed ID: 24881993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nebivolol: a review.
    Cockcroft J
    Expert Opin Pharmacother; 2004 Apr; 5(4):893-9. PubMed ID: 15102571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tempol-nebivolol therapy potentiates hypotensive effect increasing NO bioavailability and signaling pathway.
    Bertera FM; Santa-Cruz DM; Balestrasse KB; Gorzalczany SB; Höcht C; Taira CA; Polizio AH
    Free Radic Res; 2014 Feb; 48(2):109-18. PubMed ID: 24074298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension.
    Germino FW
    Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A review of the safety and efficacy of nebivolol in the mildly hypertensive patient.
    Cockcroft J
    Vasc Health Risk Manag; 2007; 3(6):909-17. PubMed ID: 18200810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nebivolol: an endothelium-friendly selective β1-adrenoceptor blocker.
    Gao Y; Vanhoutte PM
    J Cardiovasc Pharmacol; 2012 Jan; 59(1):16-21. PubMed ID: 21283024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effects of nebivolol on microcirculation, platelet aggregation and blood viscosity in patients with essential hypertension].
    Zadionchenko VS; Sandomirskaia AP; Adasheva TV; Gorbacheva EV; Matveev DV; Mareeva AP; Buval'tsev VI
    Kardiologiia; 2002; 42(5):14-8. PubMed ID: 12494141
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nebivolol: a review of its clinical and pharmacological characteristics.
    Gielen W; Cleophas TJ; Agrawal R
    Int J Clin Pharmacol Ther; 2006 Aug; 44(8):344-57. PubMed ID: 16961165
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Role of the L-arginine/nitric oxide system in the action of nebivolol].
    Brodde OE; Philipp T
    Dtsch Med Wochenschr; 2006 Nov; 131(45):2545-50. PubMed ID: 17091442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients.
    Himmelmann A; Hedner T; Snoeck E; Lundgren B; Hedner J
    Eur J Clin Pharmacol; 1996; 51(3-4):259-64. PubMed ID: 9010695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. β-blockers: a review of their pharmacological and physiological diversity in hypertension.
    Ripley TL; Saseen JJ
    Ann Pharmacother; 2014 Jun; 48(6):723-33. PubMed ID: 24687542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nitric oxide mechanisms of nebivolol.
    Maffei A; Lembo G
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):317-27. PubMed ID: 19443516
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nebivolol ameliorates nitric oxide deficient hypertension.
    Fortepiani LA; Ortíz MC; Atucha NM; García-Estañ J
    ScientificWorldJournal; 2002 Jun; 2():1676-84. PubMed ID: 12806161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nebivolol efficacy and safety in patients with stage I-II hypertension.
    Greathouse M
    Clin Cardiol; 2010 Apr; 33(4):E20-7. PubMed ID: 20162736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and tolerability of nebivolol: does age matter? A retrospective analysis of three randomized, placebo-controlled trials in stage I-II hypertension.
    Germino FW; Lin Y; Pejović V; Bowen L
    Ther Adv Cardiovasc Dis; 2012 Oct; 6(5):185-99. PubMed ID: 23008339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protective effects of nebivolol and reversal of endothelial dysfunction in diabetes associated with hypertension.
    Georgescu A; Popov D; Dragan E; Dragomir E; Badila E
    Eur J Pharmacol; 2007 Sep; 570(1-3):149-58. PubMed ID: 17612521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.